The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2
10 Takeover Targets of 2018
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
puma biotechnology buyout Off 58% - canerofset.com
Puma to price new cancer med Nerlynx at a higher-than-expected $10K per month: report | FiercePharma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
puma biotechnology buyout Off 58% - canerofset.com
Puma Biotechnology
puma biotechnology buyout Off 58% - canerofset.com
Biotech Stocks Post Double-Digit Gains in Monday Surge - TheStreet
puma biotechnology buyout Off 67% - www.otostech.com
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
puma biotechnology glassdoor Off 64% - canerofset.com
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
Puma Biotechnology Inc - AnnualReports.com
Puma Biotechnology Inc - AnnualReports.com
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology Reports Second Quarter 2021 Financial Results | Business Wire
